Alyeska Investment Group
ELEV

Alyeska Investment Group’s Elevation Oncology ELEV Stock Holding History

Alyeska Investment Group’s Portfolio ELEV Stock Details ELEV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-125,000
Closed -$1.7M – 709
2021
Q2 		$1.7M Buy
+125,000
New +$1.54M 0.02% 537

Other funds holding ELEV

ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Alyeska Investment Group's ELEV Position: Q3 2021 in Review

Alyeska Investment Group sold out of Elevation Oncology (ELEV) in Q3 2021, closing a stake of 125,000 shares — an estimated $1.7M sold.

Alyeska Investment Group first reported a position in ELEV in Q2 2021 and held it in 1 quarter. The position peaked at $1.7M in Q2 2021. 22 funds tracked by Wall St. Rank hold ELEV as of Q3 2021.

  • Alyeska Investment Group reported no remaining Elevation Oncology position as of Q3 2021 after selling out during the quarter.
  • Alyeska Investment Group sold 125,000 Elevation Oncology shares in Q3 2021, an estimated $1.7M.
  • Alyeska Investment Group first reported a position in Elevation Oncology in Q2 2021 and held it in 1 quarter.
  • Alyeska Investment Group's Elevation Oncology position peaked at $1.7M in Q2 2021.
  • 22 funds tracked by Wall St. Rank held Elevation Oncology as of Q3 2021.

Based on Alyeska Investment Group's 13F filing for Q3 2021, filed 15 Nov 2021.